Quantics Biostatistics

What Quantics Biostatistics does

Quantics Biostatistics is a privately-held UK biostatistical consultancy and software provider headquartered in Edinburgh, founded in 2002 by statistician Ann Yellowlees. The firm serves pharmaceutical, biotechnology, vaccine, medical device, agrochemical, food, and public-sector life sciences organizations requiring regulatory-grade statistical analysis that is typically uneconomical to build in-house. Service lines span bioassay development (relative potency, ELISA, validation under USP 1033), clinical trial biostatistics (study design, sample size, PK/PD, adaptive design, CDISC reporting), Health Technology Assessment (network meta-analysis, MAIC, survival analysis for NICE submissions), bioequivalence, GxP/GLP statistics, vaccine correlates of immunity, and ecotoxicology.

The company monetizes through three revenue streams: professional services engagements sold directly to enterprise clients (e.g., Roche, Ipsen, PharmAthene, Danone, Syngenta, NHS Trusts), QuBAS software licensing on a subscription basis with a freemium trial entry point (QuBAS Now), and fee-based training courses in bioassay and introductory statistics. QuBAS, the proprietary core product, encodes pre-programmed USP and PhEUR standard models, suitability criteria, the proprietary Bursa-Yellowlees interpolation method, and Continuous real-time Validation (CrtV), with a Routine mode certified to GxP and 21 CFR Part 11 standards; the firm itself operates under an ISO 9001-accredited quality management system. Distribution is dual-motion: enterprise consulting through direct sales alongside a product-led self-serve motion for QuBAS, supported by an extensive topic-organized blog, two published books, and structured training programs that double as demand generation.

Quantics is founder/owner-operated with no disclosed external investment, subsidiaries, or parent company, and employs a senior team of PhD-level statisticians and software engineers led by CEO Philip Speakman. The company maintains long-tenured client relationships (including a 14-year collaboration with Caritas Bioscience) and has gradually expanded therapeutic-area coverage into Cell & Gene Therapy, Oncology, and Infectious Diseases while deepening its regulatory-compliance positioning as a defensible niche in a market dominated by larger CROs.

Name

Quantics Biostatistics

Legal name

Quantics Biostatistics

Website

https://quantics.co.uk

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Quantics Biostatistics is an Edinburgh-based biostatistical consultancy and QuBAS software provider, founded in 2002, serving pharmaceutical, biotech, vaccine, and life sciences clients with regulatory-grade bioassay, clinical trial, and HTA statistical analysis under ISO 9001 and GxP compliance.

Ownership category

akta.pro rank

Headquarters

HQ city

Edinburgh

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biostatistical Consultancy Services: Expert consultancy services providing statistical support for bioassay development, clinical trials, vaccine development, Health Technology Assessment (HTA), bioequivalence studies, GxP/GLP statistics, and ecotoxicology.
2. QuBAS Software Licensing: Software product for bioassay analysis available with free trial and subscription pricing models.
3. Training Services: Expert-led training courses in bioassay statistics and introductory statistics for the life sciences industry.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Quantics Biostatistics is a UK-based biostatistical consultancy and software provider serving the life science industry since 2002. The company delivers expert statistical consultancy across bioassay development, clinical trials, vaccine development, health technology assessment (HTA), bioequivalence, GxP/GLP studies, and ecotoxicology, and sells QuBAS, a proprietary click-and-drag statistical analysis software for relative potency and ELISA assays with built-in USP/PhEUR standard models and GxP/21 CFR Part 11 compliance. Training services in bioassay and introductory statistics round out the offering.

Product overview

Quantics Biostatistics is a biostatistical consultancy and software provider for the life science industry, established since 2002. The company offers QuBAS as its primary proprietary bioassay software product, complemented by expert statistical consultancy services across multiple domains including bioassay development, clinical trials, health technology assessment, bioequivalence, GxP/GLP compliance, vaccine development, and ecotoxicology. The portfolio consists of QuBAS software for statistical analysis of relative potency and ELISA assays, combined with specialized consultancy services and training programs delivered by highly qualified statistical, scientific, and medical staff.

Differentiator

Problem solved

Functional benefit

Brands

• QuBAS: Feature-rich statistical analysis software package for relative potency and ELISA assays. Provides USP and PhEUR standard models with GxP and 21 CFR pt11 compliance.

Products and services

• QuBAS Bioassay Software

Quantifiable outcome

• Prob(OOS) target of less than 1% when true relative potency is 100% using properly justified acceptance criteria
• +2 more outcomes

Named customers11 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered notable.

• RoukenBionotableStrategic or Co-development PartnerOngoing collaboration with RoukenBio (Immunology CRO redefined) on bioassay development content, including joint blog posts on cell substrates, design of experiments, and response modelling for potency assays.
• ByondisnotableTechnology or IntegrationByondis is a QuBAS software user, utilizing Quantics' bioassay analysis software for their research and development activities.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Parexel International: Parexel is a global CRO offering biostatistics, clinical operations and regulatory services. Comparable to Quantics as a competitor for outsourced biostatistics work, though at far greater scale and breadth.
• SAS Institute (JMP): JMP, a division of SAS, provides statistical discovery software widely used in life sciences R&D and quality. It overlaps with QuBAS for advanced statistical analysis in pharma and represents a broader, established incumbent in the scientific statistics software market.
• GraphPad (Dotmatics): GraphPad Prism is a widely used scientific statistics software package now part of Dotmatics. It overlaps with QuBAS for general bioassay and life sciences statistical analysis, though it lacks Quantics' USP/PhEUR-specific pre-programming and 21 CFR Part 11 compliance.
• ICON plc: ICON is a global full-service CRO with extensive biostatistics, clinical and regulatory capabilities. It competes with Quantics on larger biostatistics engagements and represents the bundled-vendor alternative to specialist biostatistics providers.

Direct peers

• Berry Consultants: Berry Consultants is a statistical consulting firm specialising in Bayesian adaptive clinical trial design and biostatistics for pharma. Comparable to Quantics' biostatistics consultancy practice, particularly around advanced trial design and regulatory-facing analysis.
• Cytel: Cytel is a large biostatistics-focused CRO serving pharma and biotech with statistical consulting, clinical trial design and software (East, Solara). It is the most direct competitor to Quantics' biostatistics consultancy model, though at materially greater scale and with broader clinical trial scope.
• Stegmann Systems (PLA software): Stegmann Systems develops PLA, a software package for parallel-line bioassay statistical analysis aligned with European Pharmacopoeia standards. It is the closest direct competitor to QuBAS for bioassay statistical software in pharma QC and regulatory environments.
• Phastar: Phastar is a specialist biostatistics, data science and statistical programming CRO serving clinical trials, real-world evidence and regulatory submissions. It is a direct peer given overlapping biostatistics consulting services and similar mid-sized, specialist positioning.
• Rho: Rho is a contract research organisation providing biostatistics, clinical research and regulatory services to biopharma. It is a direct peer in biostatistics and clinical trial statistical support, with a comparable mid-sized CRO profile.

Emerging players

• EDQM (CombiStats): CombiStats, distributed by the European Directorate for the Quality of Medicines, is free software implementing PhEUR bioassay statistical models. It is a direct functional alternative to QuBAS' routine analyses and constrains Quantics' pricing power at the entry tier.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/quanticsbiostatistics
• LinkedInlinkedin.com/company/quantics-consulting

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quantics Biostatistics